Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Radiation Oncology Journal, published by the Korean Society of Therapeutic Radiology & Oncology, stands at the forefront of cancer treatment research and innovation within the dynamic fields of oncology and radiology. With a focus on disseminating groundbreaking findings and advancements from 2012 to 2024, this journal aims to foster collaboration among researchers, clinicians, and educators dedicated to improving therapeutic techniques and patient outcomes in the context of radiation therapy. Recognized with a prestigious Q2 ranking in both the Oncology and Radiology, Nuclear Medicine and Imaging categories, it ranks 140th out of 333 in its Scopus category for Medicine Radiology and boasts a 58th percentile placement. While operating on a non-open access basis, the journal remains committed to providing valuable insights and updates to professionals in the field from its base in South Korea. As the landscape of cancer treatment evolves, the Radiation Oncology Journal continues to play a vital role in shaping research trends and enhancing the understanding of radiotherapy's role in comprehensive cancer care.

Physica Medica - European Journal of Medical Physics is a premier peer-reviewed journal published by ELSEVIER SCI LTD, dedicated to advancing the field of medical physics. Established in 1989 and serving as a critical platform for innovative research, this journal covers a broad spectrum of topics within biophysics, radiology, and imaging sciences, consistently ranked in the Q1 category across these disciplines. With an impressive impact factor that highlights its influence within the scientific community—ranking 52/333 in Radiology, 42/243 in Physics and Astronomy, and 35/152 in Biochemistry—the journal is a valuable resource for professionals, researchers, and students aiming to contribute to the technological and methodological advancements in medical physics. Physica Medica is committed to fostering open dialogue and collaboration within the global medical physics community, although it currently does not offer open access options. The journal's extensive citation history and ongoing relevance underscore its importance in the continuous evolution of medical science.

MEDICAL PHYSICS, published by WILEY, stands as a leading journal in the fields of biophysics, medicine, and radiology, boasting an impressive impact factor and classified within the prestigious Q1 category across multiple relevant domains. With its ISSN 0094-2405 and E-ISSN 2473-4209, the journal has been a vital resource since its inception in 1974, leading the discourse well into 2024. Hailing from the United States, MEDICAL PHYSICS serves a diverse academic audience, comprising researchers, clinicians, and students eager to engage with the latest advancements and methodologies. The journal’s authoritative presence is underscored by its Scopus rankings, placing it among the top percentile in both Medicine and Biophysics, marking it as an essential scholarly platform for innovative research and critical reviews. While not currently an Open Access journal, its commitment to curating high-quality articles ensures that readers can access groundbreaking insights into medical imaging, treatment protocols, and the theoretical underpinnings of medical physics. Explore the intersection of technology and healthcare through the esteemed pages of MEDICAL PHYSICS.

SEMINARS IN RADIATION ONCOLOGY is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, dedicated to advancing the field of radiation oncology through high-quality research and comprehensive reviews. With an impressive impact factor and a notable HIndex, this journal holds a prominent place within the academic community, particularly illustrated by its Q2 ranking in both Cancer Research and Oncology, and a Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. Since its inception in 1991, the journal has served as a vital resource for researchers, clinicians, and healthcare professionals, facilitating the exchange of innovative ideas and practices that shape the future of cancer treatment. While the journal is not open access, it offers essential insights into the latest advancements in the field, catering to a diverse audience eager to expand their knowledge and improve patient outcomes in the realm of radiation therapy.

Advances in Radiation Oncology, published by Elsevier Inc, is a premier international journal dedicated to the field of oncology and radiology, focusing on the latest groundbreaking research and innovations in radiation therapy. Launched as an Open Access journal in 2016, it has since carved out a significant niche in the academic community, featuring contributions that span a diverse range of topics including clinical practices, technologies, and outcomes in radiation oncology. With an impressive Q2 rankingOncology and Radiology, Nuclear Medicine and Imaging categories for 2023, and positioned within the 65th and 55th percentiles of Scopus ranks, it serves as an essential resource for researchers, medical professionals, and students alike. The journal not only emphasizes the importance of disseminating knowledge widely through its open access model but also aims to foster collaboration and innovation in the evolving landscape of cancer treatment. For those looking to stay at the forefront of radiotherapy research and advancements, Advances in Radiation Oncology is an invaluable platform for scholarly communication.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

International Journal of Particle Therapy, an esteemed publication from the INT JOURNAL PARTICLE THERAPY, stands at the forefront of innovative research in the realms of particle therapy, radiology, and atomic physics. Established as an Open Access journal since 2015, it provides a platform for scholarly articles that drive the advancement of knowledge and practice in cancer treatment and radiation therapy. With an impact factor reflective of its rising stature, this journal has been categorized in the Q2 quartile for both Atomic and Molecular Physics and Radiology, Nuclear Medicine and Imaging as of 2023, illustrating its significant role in contributing to these vital fields. Researchers, professionals, and students alike will find the journal indispensable for accessing pioneering studies that explore the efficacy and application of particle therapy, ensuring that the latest advancements reach a broad audience. With a robust focus on bridging theoretical insights and clinical practices, the International Journal of Particle Therapy remains committed to enhancing patient outcomes and fostering collaboration among scientists worldwide.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.